{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:30:03Z","timestamp":1787009403449,"version":"build-2736575974"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2017,7,19]],"date-time":"2017-07-19T00:00:00Z","timestamp":1500422400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,4,1]]},"DOI":"10.1093\/ndt\/gfx188","type":"journal-article","created":{"date-parts":[[2017,4,20]],"date-time":"2017-04-20T15:08:59Z","timestamp":1492700939000},"page":"645-652","source":"Crossref","is-referenced-by-count":39,"title":["Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial"],"prefix":"10.1093","volume":"33","author":[{"given":"Emilie","family":"Cornec-Le Gall","sequence":"first","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN 55902, USA"},{"name":"European University of Western Brittany, CHU Brest, Brest, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime D","family":"Blais","sequence":"additional","affiliation":[{"name":"Otsuka PDC, Rockville, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria V","family":"Irazabal","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN 55902, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Devuyst","sequence":"additional","affiliation":[{"name":"Institute of Nephrology, University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron T","family":"Gansevoort","sequence":"additional","affiliation":[{"name":"Department of Nephrology, University Medical Center of Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron D","family":"Perrone","sequence":"additional","affiliation":[{"name":"Tufts Medical Center, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene B","family":"Chapman","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University of Chicago, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank S","family":"Czerwiec","sequence":"additional","affiliation":[{"name":"Otsuka PDC, Rockville, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Ouyang","sequence":"additional","affiliation":[{"name":"Otsuka PDC, Rockville, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina M","family":"Heyer","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN 55902, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah R","family":"Senum","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN 55902, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Le Meur","sequence":"additional","affiliation":[{"name":"European University of Western Brittany, CHU Brest, Brest, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente E","family":"Torres","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN 55902, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C","family":"Harris","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN 55902, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,7,19]]},"reference":[{"key":"key\n\t\t\t\t20180626083744_gfx188-B1","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1053\/j.ajkd.2015.07.037","article-title":"Autosomal dominant polycystic kidney disease: core curriculum 2016","volume":"67","author":"Chebib","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t20180626083744_gfx188-B2","doi-asserted-by":"crossref","first-page":"iv15","DOI":"10.1093\/ndt\/gfu017","article-title":"Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival\u2014an analysis of data from the ERA-EDTA Registry","volume":"29(Suppl 4)","author":"Spithoven","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20180626083744_gfx188-B3","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1681\/ASN.2012070650","article-title":"Type of PKD1 mutation influences renal outcome in ADPKD","volume":"24","author":"Cornec-Le Gall","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180626083744_gfx188-B4","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1681\/ASN.2015010016","article-title":"The PROPKD score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease","volume":"27","author":"Cornec-Le Gall","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180626083744_gfx188-B5","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1002\/humu.22708","article-title":"Genetics and pathogenesis of autosomal dominant polycystic kidney disease: twenty years on","volume":"35","author":"Cornec-Le Gall","year":"2014","journal-title":"Hum Mutat"},{"key":"key\n\t\t\t\t20180626083744_gfx188-B6","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrneph.2010.18","article-title":"Molecular diagnostics for autosomal dominant polycystic kidney disease","volume":"6","author":"Harris","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"key\n\t\t\t\t20180626083744_gfx188-B7","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1681\/ASN.2015050583","article-title":"Predicted mutation strength of nontruncating PKD1 mutations aids genotype\u2013phenotype correlations in autosomal dominant polycystic kidney disease","volume":"27","author":"Heyer","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180626083744_gfx188-B8","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1681\/ASN.2015060648","article-title":"Refining genotype\u2013phenotype correlation in autosomal dominant polycystic kidney disease","volume":"27","author":"Hwang","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180626083744_gfx188-B9","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.ajhg.2016.05.004","article-title":"Mutations in GANAB, encoding the glucosidase II\u03b1 subunit, cause autosomal-dominant polycystic kidney and liver disease","volume":"98","author":"Porath","year":"2016","journal-title":"Am J Hum Genet"},{"key":"key\n\t\t\t\t20180626083744_gfx188-B10","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/S0140-6736(15)60907-2","article-title":"Autosomal dominant polycystic kidney disease: the changing face of clinical management","volume":"385","author":"Ong","year":"2015","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180626083744_gfx188-B11","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180626083744_gfx188-B12","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2215\/CJN.06300615","article-title":"Effect of tolvaptan in autosomal dominant polycystic kidney disease by CKD stage: results from the TEMPO 3:4 trial","volume":"11","author":"Torres","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180626083744_gfx188-B13","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s00467-014-2882-8","article-title":"Rationale for early treatment of polycystic kidney disease","volume":"30","author":"Grantham","year":"2015","journal-title":"Pediatr Nephrol"},{"key":"key\n\t\t\t\t20180626083744_gfx188-B14","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/ki.2015.71","article-title":"A comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease","volume":"88","author":"Bhutani","year":"2015","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20180626083744_gfx188-B15","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2215\/CJN.09500911","article-title":"Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease","volume":"7","author":"Chapman","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180626083744_gfx188-B16","author":"European Medicines Agency","year":"2015"},{"key":"key\n\t\t\t\t20180626083744_gfx188-B17","author":"US Food and Drug Administration"},{"key":"key\n\t\t\t\t20180626083744_gfx188-B18","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/nrneph.2016.135","article-title":"The importance of total kidney volume in evaluating progression of polycystic kidney disease","volume":"12","author":"Grantham","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"key\n\t\t\t\t20180626083744_gfx188-B19","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1056\/NEJMoa054341","article-title":"Volume progression in polycystic kidney disease","volume":"354","author":"Grantham","year":"2006","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180626083744_gfx188-B20","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1681\/ASN.2013101138","article-title":"Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials","volume":"26","author":"Irazabal","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180626083744_gfx188-B21","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1053\/j.ajkd.2010.11.029","article-title":"Rationale and design of the TEMPO (tolvaptan efficacy and safety in management of autosomal dominant polycystic kidney disease and its outcomes) 3\u20134 study","volume":"57","author":"Torres","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t20180626083744_gfx188-B22","article-title":"Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial","author":"Torres"},{"key":"key\n\t\t\t\t20180626083744_gfx188-B23","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1038\/ki.2008.485","article-title":"Characterization of large rearrangements in autosomal dominant polycystic kidney disease and the PKD1\/TSC2 contiguous gene syndrome","volume":"74","author":"Consugar","year":"2008","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20180626083744_gfx188-B24","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1681\/ASN.2006121387","article-title":"Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease","volume":"18","author":"Rossetti","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180626083744_gfx188-B25","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20180626083744_gfx188-B26","doi-asserted-by":"crossref","first-page":"e0116680","DOI":"10.1371\/journal.pone.0116680","article-title":"An efficient and comprehensive strategy for genetic diagnostics of polycystic kidney disease","volume":"10","author":"Eisenberger","year":"2015","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180626083744_gfx188-B27","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1681\/ASN.2011101032","article-title":"Identification of gene mutations in autosomal dominant polycystic kidney disease through targeted resequencing","volume":"23","author":"Rossetti","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180626083744_gfx188-B28","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/humu.20842","article-title":"Novel method for genomic analysis of PKD1 and PKD2 mutations in autosomal dominant polycystic kidney disease","volume":"30","author":"Tan","year":"2009","journal-title":"Hum Mutat"},{"key":"key\n\t\t\t\t20180626083744_gfx188-B29","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/mgg3.82","article-title":"Diagnosis of autosomal dominant polycystic kidney disease using efficient PKD1 and PKD2 targeted next-generation sequencing","volume":"2","author":"Trujillano","year":"2014","journal-title":"Mol Genet Genomic Med"},{"key":"key\n\t\t\t\t20180626083744_gfx188-B30","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cca.2014.02.011","article-title":"Identification of novel mutations of PKD1 gene in Chinese patients with autosomal dominant polycystic kidney disease by targeted next-generation sequencing","volume":"433","author":"Yang","year":"2014","journal-title":"Clin Chim Acta"},{"key":"key\n\t\t\t\t20180626083744_gfx188-B31","first-page":"1857","article-title":"Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial","volume":"32","author":"Irazabal","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20180626083744_gfx188-B32","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ekir.2016.08.001","article-title":"Prognostic enrichment design in clinical trials for ADPKD: the TEMPO 3:4 clinical trial","volume":"1","author":"Irazabal","year":"2016","journal-title":"Kidney Int Rep"},{"key":"key\n\t\t\t\t20180626083744_gfx188-B33","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1402685","article-title":"Blood pressure in early autosomal dominant polycystic kidney disease","volume":"371","author":"Schrier","year":"2014","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180626083744_gfx188-B34","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/ndt\/gfv456","article-title":"Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice","volume":"31","author":"Gansevoort","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20180626083744_gfx188-B35","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ymgme.2007.05.004","article-title":"Evaluating the clinical utility of a molecular genetic test for polycystic kidney disease","volume":"92","author":"Garcia-Gonzalez","year":"2007","journal-title":"Mol Genet Metab"},{"key":"key\n\t\t\t\t20180626083744_gfx188-B36","doi-asserted-by":"crossref","first-page":"16981","DOI":"10.1073\/pnas.252484899","article-title":"Cleavage of polycystin-1 requires the receptor for egg jelly domain and is disrupted by human autosomal-dominant polycystic kidney disease 1-associated mutations","volume":"99","author":"Qian","year":"2002","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/33\/4\/645\/25091449\/gfx188.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,21]],"date-time":"2019-09-21T08:27:39Z","timestamp":1569054459000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/33\/4\/645\/3979612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,19]]},"references-count":36,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,7,19]]},"published-print":{"date-parts":[[2018,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfx188","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.731968970.793555209","asserted-by":"object"}]},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,4]]},"published":{"date-parts":[[2017,7,19]]}}}